Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.68 |
| ▸ | MMP2 | P08253 | 2/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | MMP1 | P03956 | 1/20 | 0.68 |
| ▸ | MMP9 | P14780 | 1/20 | 0.68 |
| ▸ | MMP8 | P22894 | 1/20 | 0.68 |
| ▸ | MMP13 | P45452 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 3/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362188 | 0.85 | ALOX5 (0.69) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL6840610 | 0.85 | CA2 (0.64) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL9301309 | 0.84 | CA2 (0.62) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL9301881 | 0.84 | CA2 (0.62) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL15055133 | 0.84 | CA2 (0.62) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL7211717 | 0.82 | KMT2A (0.63) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL6849866 | 0.81 | CA2 (0.62) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL9301816 | 0.81 | CA2 (0.62) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL6469330 | 0.81 | CA2 (0.67) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL1969168 | 0.81 | CA2 (0.58) | CA2MMP2CA1MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100396663-C | Preparation method of N-[(3-aminophenyl) sulfuryl] acetamide | SHENYANG RES INST CHEMICAL IND (CN) | 2008-06-25 | — | — | CN | claimed |
| CN-1869015-A | Preparation method of N-[(3-aminophenyl) sulfuryl] acetamide | SHENYANG INST OF CHEMICAL INDU (CN) | 2006-11-29 | — | — | CN | claimed |
| CN-117603101-A | Lewis acid-promoted non-hydrolytic deacylation method for N-acyl secondary sulfonamide | 荆楚理工学院 | 2024-02-27 | — | — | CN | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
| EP-2027081-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2016-07-28 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160106731-A1 | TRICYCLIC INDOLE MCL-1 INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-21 | — | — | US | disclosed |
| EP-2046714-B1 | Cyclopentane derivatives as antiglaucoma agents | ALLERGAN INC (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2015148854-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007115020-A2 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| CN-1869015-A | Preparation method of N-[(3-aminophenyl) sulfuryl] acetamide | SHENYANG INST OF CHEMICAL INDU (CN) | 2006-11-29 | — | — | CN | disclosed |
| EP-0508796-B1 | Cholecystokinin antagonists | MERCK & CO INC (US) | 1998-07-08 | — | — | EP | disclosed |
| US-5360802-A | Antagonists of cholecystokinin and gastrin | MERCK SHARPE & DOHME LTD. | 1994-11-01 | — | — | US | disclosed |
| US-5220018-A | Benzodiazepine derivatives | MERCK & CO., INC. (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0538945-A1 | Benzodiazepine derivatives, and their use as antagonists of gastrin and/or cholecystokinin | GLAXO GROUP LIMITED (GB) | 1993-04-28 | — | — | EP | disclosed |
| EP-0514133-A1 | Benzodiazepine derivatives, compositions containing them and their use in therapy | MERCK SHARP & DOHME LTD. (GB) | 1992-11-19 | — | — | EP | disclosed |
| EP-0508796-A1 | Cholecystokinin antagonists | MERCK & CO. INC. (US) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2, BCL2L1 | CA2 3872/4885MMP2 2999/4885CA1 3557/4885 |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | CA2 2527/4885MMP2 519/4885CA1 3439/4885 |
| US-20160106731-A1 | TRICYCLIC INDOLE MCL-1 INHIBITORS AND USES THEREOF | MCL1, BCL2L1, BCL3 | CA2 4211/4885MMP2 3792/4885CA1 4252/4885 |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | CA2 4564/4885MMP2 4199/4885CA1 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.